In 2021, Jiang group developed two highly selective and functional EGFR-targeting PROTAC 30 (SIAIS125, Fig. 7) and 31 (SIAIS126, Fig. 7) based on Canertinib and CRBN ligand.57 Interestingly, they induced sustaining and selective degradation of EGFRL858R/T790M in H1975 cells and EGFRe19d in PC9 cells rather than EGFREe19d/T790M in PC9Brca1 cells and EGFRWT in A549 cells, which led to the selective growth inhibition of EGFR mutant lung cancer cells instead of normal cells or A549 cells. The gene discussed is EGFR; the disease is lung carcinoma.